Beatriz Grinsztejn

Stories

A twice-yearly HIV shot arrives as funding to deliver it shrinks

Hosting AIDS 2026 in her home country

On Nov. 2, the U.S. Food and Drug Administration gave tentative approval to a generic version of lenacapavir made by India's Dr. Reddy's Laboratories. The twice-yearly shot is expected to sell for about $40 per person per year in 120 low- and middle-income countries. It cannot be sold in the U.S.

Updated 5 days ago